Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome

Efe C., Ozaslan E., KAV T. , Purnak T. , Shorbagi A., ÖZKAYAR Ö. , ...More

AUTOIMMUNITY REVIEWS, vol.11, no.5, pp.330-334, 2012 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 11 Issue: 5
  • Publication Date: 2012
  • Doi Number: 10.1016/j.autrev.2011.09.006
  • Title of Journal : AUTOIMMUNITY REVIEWS
  • Page Numbers: pp.330-334


Background and aim: The aim of the present study was to assess the efficacy and tolerability of budesonide as an alternative first line treatment option for autoimmune hepatitis (AIH) and the overlap syndrome.